Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Versanis
Oakland, California, United Statesversanisbio.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Versanis’ lead asset bimagrumab, a first-in-class, fully human monoclonal antibody targeting activin type II receptors, is in Phase 2b (BELIEVE study) for obesity and cardiometabolic disease. Bimagrumab has shown ability to drive significant fat loss while increasing muscle mass, either alone or in combination with semaglutide[1][3][8].
- Therapeutic areas
- EndocrinologyCardiovascular
- Modalities
- Monoclonal antibodyBiologic
- Industry
- Biotech
02
Partnerships
Beyond the preview
Go deeper on Versanis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Versanis.